HM-3 is under clinical development by Inner Mongolia Qite Biotechnology (Group) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HM-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HM-3 is under development for the treatment of solid tumors including non-small cell lung, liver, gastric, breast cancer. It is administered through parenteral route. It acts by targeting cells expressing integrin alpha 5 (ITGAV) and beta 3 (ITGB3) receptors.
For a complete picture of HM-3’s drug-specific PTSR and LoA scores, buy the report here.